贝伐珠单抗抗血管机制解析.pptVIP

获得性耐药，很大程度上由于基因不稳定（基因突变、扩增、缺失等），而作用于微环境的抗血管药物很少出现有获得性耐药3 * 人结肠癌(SW620，使用抗VEGF抗体B20-4.1和B20-4.1.1作为贝伐珠单抗的替代品 * * * * Avastin has demonstrated to increase survival (either PFS or OS) in 6 different tumor types including Ovarian cancer, where we reported two positive phase III studies in 2010 (GOG 218 and ICON-7). Ovarian cancer has been filed in the EU and the US filing is planned for Q4’2011. Last year we also reported that trials in Prostate, Gastric and adjuvant Colon Cancer missed their primary endpoints. * 持续使用贝伐珠单抗抑制血管生成，持续控制肿瘤1–3 一线并持续抑制VEGF是转移性肿瘤患者的重要治疗策略1–6 * 1. Mabuchi, et al. Clin